See more : Chorus Limited (CNU.AX) Income Statement Analysis – Financial Results
Complete financial analysis of PolyPid Ltd. (PYPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PolyPid Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fresenius SE & Co. KGaA (FRE.SW) Income Statement Analysis – Financial Results
- Ashland Inc. (ASH) Income Statement Analysis – Financial Results
- Drewloong Precision, Inc. (4572.TW) Income Statement Analysis – Financial Results
- Chong Fai Jewellery Group Holdings Company Limited (8537.HK) Income Statement Analysis – Financial Results
- Evergreen Corporation (EVGR) Income Statement Analysis – Financial Results
PolyPid Ltd. (PYPD)
About PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 0.00 | 0.00 |
| Gross Profit | -1.82M | -1.72M | -1.12M | -1.01M | -947.00K | -411.00K | -205.00K | -127.00K | -108.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.15M | 27.99M | 30.42M | 16.95M | 14.08M | 12.55M | 9.74M | 7.71M | 5.63M | 2.64M | 1.38M |
| General & Administrative | 0.00 | 8.01M | 9.48M | 7.70M | 4.48M | 5.27M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Selling & Marketing | 0.00 | 2.89M | 2.97M | 1.61M | 887.00K | 549.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.90M | 10.90M | 12.45M | 9.32M | 4.48M | 5.81M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.05M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Cost & Expenses | 22.87M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Interest Income | 548.00K | 267.00K | 468.00K | 474.00K | 60.00K | 126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.71M | 1.02M | 0.00 | 17.00K | 15.00K | 42.00K | 40.69M | 1.13M | -1.53M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 71.00K | 60.00K |
| EBITDA | -20.26M | -36.37M | -41.48M | -35.86M | -5.94M | -42.15M | -13.60M | -10.13M | -7.95M | -3.51M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.87M | -38.89M | -42.88M | -26.27M | -18.56M | -18.36M | -13.80M | -10.26M | -11.28M | -3.58M | -1.79M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -929.00K | -540.00K | 544.00K | -10.60M | 11.66M | 24.28M | -40.69M | -1.13M | -1.18M | -305.00K | -3.00K |
| Income Before Tax | -23.80M | -39.43M | -42.33M | -36.87M | -6.91M | 5.92M | -54.49M | -11.39M | -9.75M | -3.88M | -1.79M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 69.00K | 97.00K | -1.62M | -1.55M | -11.66M | -24.28M | 40.69M | 1.13M | -1.53M | 305.00K | 3.00K |
| Net Income | -23.87M | -39.53M | -40.71M | -35.32M | 4.75M | 5.92M | -54.49M | -11.39M | -8.22M | -3.88M | -1.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| EPS Diluted | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| Weighted Avg Shares Out | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
| Weighted Avg Shares Out (Dil) | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022
PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before...
PolyPid: Strong Pipeline, Close Catalysts
PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications. Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdominal surgical site infections serving a huge market.
PolyPid to Present at the Barclays Global Healthcare Conference
PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present...
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q4 2021 Results - Earnings Call Transcript
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q4 2021 Results - Earnings Call Transcript
PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022
PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report...
PolyPid's (PYPD) CEO Amir Weisberg on Q3 2021 Results - Earnings Call Transcript
PolyPid's (PYPD) CEO Amir Weisberg on Q3 2021 Results - Earnings Call Transcript
PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021
PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report...
PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor
PolyPid Ltd (NASDAQ: PYPD) has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. OncoPLEX is designed to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy agents.
PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer
PETAH TIKVA, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced positive preclinical data in two key...
PolyPid Ltd's (PYPD) CEO Amir Weisberg on Q2 2021 Results - Earnings Call Transcript
PolyPid Ltd's (PYPD) CEO Amir Weisberg on Q2 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports